Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company whose news flow reflects its role in life science tools, bioactive reagents, diagnostics, and spatial biology. Company announcements frequently highlight financial results, product launches, collaborations, and participation in healthcare and investor conferences, giving investors and researchers insight into how Bio-Techne is executing its strategy.
Recent press releases include quarterly and annual financial updates, where Bio-Techne reports net sales, segment performance for its Protein Sciences and Diagnostics and Spatial Biology segments, and commentary on market conditions. These earnings communications often discuss organic revenue trends, operating margins, and portfolio decisions such as divestitures of non-core businesses.
Product and technology news from Bio-Techne covers launches of analytical instruments, spatial biology assays, and multiomic workflows. Examples include announcements of next-generation protein analysis systems with multiplexing capabilities, spatial biology platforms that combine RNA and protein detection, and assays that visualize protein-protein interactions within tissue at subcellular resolution. Such updates show how the company is expanding its proteomic analytical tools and spatial biology offerings, which it identifies as growth pillars.
Bio-Techne also issues news about strategic collaborations and licensing agreements. Recent items describe partnerships in AI-enabled protein design, multiomic spatial analysis with academic and industry partners, and initiatives supporting cell and gene therapy manufacturing workflows. In addition, the company regularly announces its participation in major healthcare and investor conferences, where management presents its outlook and strategy.
This TECH news page aggregates these types of updates so readers can follow Bio-Techne’s financial reporting, product innovation, strategic partnerships, and conference activity in one place. Investors, analysts, and scientists can use this feed to monitor developments across the company’s life science tools, diagnostics, and spatial biology businesses.
Bio-Techne (NASDAQ: TECH) reported its Q4 and full-year fiscal 2025 results, with Q4 organic revenue growing 3% (4% reported) to $317.0 million. Full-year organic revenue increased 5% to $1.2 billion. The company reported Q4 GAAP EPS of $(0.11) versus $0.25 year-over-year, while adjusted EPS improved to $0.53 from $0.49.
The Protein Sciences segment showed strong performance with 4% organic growth (6% reported) in Q4. Notably, Bio-Techne announced the divestiture of its Exosome Diagnostics business, resulting in an $83.1 million impairment loss. The company's Q4 adjusted operating margin was 32.0%, down from 33.5% in the previous year, impacted by unfavorable product mix.
Bio-Techne (NASDAQ: TECH) has announced the divestiture of its Exosome Diagnostics business to Mdxhealth SA. The deal includes the ExoDx Prostate (EPI) test, CLIA-certified clinical laboratory, and related assets. Bio-Techne will maintain access to the proprietary exosome-based technology for kit development in its precision diagnostics segment.
Under the agreement terms, Bio-Techne will receive $5 million in MDXH stock plus future considerations. The transaction is expected to close in Q1 of Bio-Techne's fiscal 2026. The strategic move aims to strengthen Bio-Techne's focus on developing high-value products for life science research and clinical diagnostics markets while improving its operating margin profile.
ScaleReady (NYSE:TECH) has awarded a $100,000 G-Rex® Grant to Sidra Medicine, a women and children's hospital in Qatar. The grant will support the development of a CD19 CAR-T cell therapy product for pediatric oncology, including access to G-CART™ process and implementation of GMP-compliant production systems.
The grant is part of ScaleReady's broader initiative that has committed over $40 million in no-cost products to recipients. Recipients can receive up to $300,000 in individual grants and gain access to exclusive support from ScaleReady's consortium of G-Rex Grant Partners. Additionally, ScaleReady has launched a free LEAN Cell & Gene™ event series in partnership with Hanson Wade to promote efficient CGT manufacturing.
ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReady, has awarded $665,000 in G-Rex® Grants to three investigators at the University of Minnesota's Center for Genome Engineering.
The grants were distributed to: Dr. Branden Moriarity ($300,000) for CAR-NK cell therapy development for ovarian cancer, Dr. Beau Webber ($240,000) for TIL therapy development for solid tumors, and Dr. Joseph Skeate ($125,000) for T-cell therapy development targeting Batten Disease.
ScaleReady's G-Rex Grant Program has now exceeded $40M in no-cost product commitments. The company has also launched a new free program called LEAN Cell & Gene™ in partnership with Hanson Wade to promote efficient CGT manufacturing practices.
Bio-Techne (NASDAQ: TECH) has scheduled its fourth quarter and fiscal 2025 financial results conference call for August 6, 2025, at 8:00 a.m. CDT. The company will host both a conference call and webcast to discuss the results.
Investors can access the call through a toll-free number (1-800-274-8461) or international number (1-203-518-9814) using Conference ID: TECHQ4. A webcast will be available on the company's investor relations website. For those unable to attend live, a replay will be accessible until September 6, 2025, using Conference ID 11159590.
Bio-Techne (NASDAQ: TECH) has formed a strategic distribution partnership with Spear Bio to expand global access to SPEAR UltraDetect™ immunoassays, focusing initially on neurology research. This follows Bio-Techne's participation in Spear Bio's $45 million Series A funding in 2024.
The partnership leverages Spear Bio's Successive Proximity Extension Amplification Reaction (SPEAR) platform, which offers sensitivity 100-1000 times higher than current immunoassay platforms. The technology targets key biomarkers for neurodegenerative diseases, including pTau 231, pTau 217, GFAP, and Nf-L, with potential applications in inflammation and oncology.
Bio-Techne (NASDAQ: TECH) has announced a strategic partnership with Spear Bio to distribute next-generation ultrasensitive immunoassays for neurodegenerative disease research. The partnership follows Bio-Techne's participation in Spear Bio's $45 million Series A funding in 2024.
The collaboration will focus on distributing Spear Bio's SPEAR platform technology, which offers 2-3 orders of magnitude higher sensitivity than current immunoassay platforms. The initial offering targets key Alzheimer's disease biomarkers including pTau 217, GFAP, Nf-L, and pTau 231.
This partnership leverages Bio-Techne's global distribution network and immunoassay expertise with Spear Bio's ultrasensitive technology to advance early disease detection and therapeutic development.
Bio-Techne (NASDAQ: TECH) announced that its Simple Western™ Technology was instrumental in supporting the FDA approval of ZEVASKYN™, the first autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), developed by Abeona Therapeutics.
The Simple Western platform was chosen for its superior capabilities in detecting and quantifying Collagen VII, a critical protein for ZEVASKYN's potency testing. The technology's advantages include picogram-level sensitivity, reproducibility, and minimal sample requirements, making it essential for GMP-compliant lot release testing of both viral vector and cell therapy components.
The platform successfully overcame complex analytical challenges in standardization and assay development, particularly in evaluating Collagen VII's tertiary structure under non-denaturing conditions.
Bio-Techne (NASDAQ: TECH) has announced a strategic distribution agreement with the U.S. Pharmacopeia (USP) to sell USP monoclonal antibody (mAb) and recombinant adeno-associated virus (AAV) reference standards alongside its analytical solutions, including the Maurice system.
The collaboration aims to support the development of monoclonal antibody and gene therapy products worldwide. With over 160 approved antibody therapies globally, the partnership addresses critical quality control needs in both mAb development and the rapidly growing gene therapy sector. The integration of USP reference standards with Bio-Techne's analytical instruments will enable therapy manufacturers to achieve reliable characterization for purity, charge, size, and identity applications throughout product development.